These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Ruess DA; Görgülü K; Wörmann SM; Algül H Drugs Aging; 2017 May; 34(5):331-357. PubMed ID: 28349415 [TBL] [Abstract][Full Text] [Related]
5. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426 [TBL] [Abstract][Full Text] [Related]
6. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Adiseshaiah PP; Crist RM; Hook SS; McNeil SE Nat Rev Clin Oncol; 2016 Dec; 13(12):750-765. PubMed ID: 27531700 [TBL] [Abstract][Full Text] [Related]
7. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions. Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069 [TBL] [Abstract][Full Text] [Related]
8. Impacting Pancreatic Cancer Therapy in Heterotypic Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145 [TBL] [Abstract][Full Text] [Related]
9. KRAS-related proteins in pancreatic cancer. Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930 [TBL] [Abstract][Full Text] [Related]
10. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874 [TBL] [Abstract][Full Text] [Related]
15. Use of nano engineered approaches to overcome the stromal barrier in pancreatic cancer. Meng H; Nel AE Adv Drug Deliv Rev; 2018 May; 130():50-57. PubMed ID: 29958925 [TBL] [Abstract][Full Text] [Related]
16. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics. Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693 [TBL] [Abstract][Full Text] [Related]
17. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival. Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927 [TBL] [Abstract][Full Text] [Related]
18. The trend toward more target therapy in pancreatic ductal adenocarcinoma. Deiana C; Agostini M; Brandi G; Giovannetti E Expert Rev Anticancer Ther; 2024 Jul; 24(7):525-565. PubMed ID: 38768098 [TBL] [Abstract][Full Text] [Related]
19. Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. Aslan M; Shahbazi R; Ulubayram K; Ozpolat B Anticancer Res; 2018 Dec; 38(12):6591-6606. PubMed ID: 30504367 [TBL] [Abstract][Full Text] [Related]